Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (61-70 of 140) with videos related to

Pageof 14
Sort By:
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
Biotechniques|July 14, 2020
Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assayHeidi Fettke, Jason A Steen, Edmond M Kwan, et al.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
The Prostate|July 13, 2021
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancerHeidi Fettke, Edmond M Kwan, Patricia Bukczynska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2021
<sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancerAmy Davies, Marcus Foo, Chun Loo Gan, et al.
Radiation Oncology (London, England)|February 14, 2024
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancerMuhammad Ali, Kendrick Koo, David Chang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialSarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, et al.
Ebiomedicine|April 9, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancerManish Kohli, Winston Tan, Tiantian Zheng, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
Pageof 14

Showing results (61-70 of 140) with videos related to

Sort By:
Pageof 14
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
Biotechniques|July 14, 2020
Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assayHeidi Fettke, Jason A Steen, Edmond M Kwan, et al.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
The Prostate|July 13, 2021
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancerHeidi Fettke, Edmond M Kwan, Patricia Bukczynska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2021
<sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancerAmy Davies, Marcus Foo, Chun Loo Gan, et al.
Radiation Oncology (London, England)|February 14, 2024
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancerMuhammad Ali, Kendrick Koo, David Chang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
<sup>177</sup>Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialSarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, et al.
Ebiomedicine|April 9, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancerManish Kohli, Winston Tan, Tiantian Zheng, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
Pageof 14